Fukushima Hiroshi, Hiratate Akira, Takahashi Masato, Mikami Ayako, Saito-Hori Masako, Munetomo Eiji, Kitano Kiyokazu, Chonan Sumi, Saito Hidetaka, Suzuki Akio, Takaoka Yuji, Yamamoto Koji
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd, 1-403, Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan.
Bioorg Med Chem. 2008 Apr 1;16(7):4093-106. doi: 10.1016/j.bmc.2008.01.016. Epub 2008 Jan 16.
Dipeptidyl peptidase IV (DPP-IV) inhibitors are promising antidiabetic drugs, and several drugs are in the developmental stage. We previously reported that the introduction of fluorine to the 4-position of 2-cyanopyrrolidine enhanced the DPP-IV inhibitory effect. In the present report, we examined the structure-activity relationship (SAR) of 2-cyano-4-fluoropyrrolidine with N-substituted glycine at the 1-position. We report the identification of a potent and stable DPP-IV inhibitor (TS-021) with a long-term persistent plasma drug concentration and a potent antihyperglycemic activity.
二肽基肽酶IV(DPP-IV)抑制剂是很有前景的抗糖尿病药物,有几种药物正处于研发阶段。我们之前报道过,在2-氰基吡咯烷的4位引入氟可增强DPP-IV抑制作用。在本报告中,我们研究了1位带有N-取代甘氨酸的2-氰基-4-氟吡咯烷的构效关系(SAR)。我们报告了一种强效且稳定的DPP-IV抑制剂(TS-021)的鉴定结果,该抑制剂具有长期持续的血浆药物浓度和强效的抗高血糖活性。